Journavx: The New Pain Kid on the Block
The FDA just approved Journavx for treatment in moderate-to-severe acute pain in adults. It is the first-in-class non-opioid pain medication. Journavx targets the pain-signaling pathway, specifically the sodium channel NaV1.8, in the peripheral nervous system before pain signals reach the brain. Since NaV1.8 is not expressed in the central nervous system, it is not expected…